3 results
Primary objective:To establish the safety and toxicity profile of individualized 166Ho-RE in patients with hepatocellular carcinoma. Secondary objectives:• To evaluate efficacy of individualized 166Ho-RE.• To evaluate biodistribution / dosimetry.•…
The primary objective of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progressionfree survival (PFS) (by independent imaging…
Primary objective:The objective of this randomized phase 2 study is to demonstrate efficacy of RE in terms of PFS in colorectal cancer patients with liver-only metastases who are candidates for palliative systemic treatment with capecitabine plus…